BI 836909Alternative Names: AMG 420
Latest Information Update: 08 Sep 2016
At a glance
- Originator Boehringer Ingelheim; Micromet Inc
- Developer Amgen; Boehringer Ingelheim
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; T-cell receptor antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma